Latest News
Takeda Pharmaceutical Company Limited
- FDA accepts Takeda zasocitinib NDA for psoriasis under priority review
- Takeda to seek Japan approval for gastric cancer drug next year
- South Korea's Mothers Pharmaceutical Faces Takeda Patent Battle Ahead of Kosdaq Listing, With Only 6 R&D Staff
- Takeda to seek Japan approval for gastric cancer drug next year
- Takeda Pharmaceutical Co. Ltd. Estimates – FWB:TKD
- Takeda Pharmaceutical Company Limited Announces New Data From VERDICT Showing Treating Adults With Intravenous ENTYVIO To Achieve Corticosteroid-Free Disease Clearance Prolongs Time To First Ulcerative Colitis-Related Complication
- Takeda Pharmaceutical Launches Orzeyful in Japan and China
- Takeda Pharmaceutical (TAK) Climbs 2.65% to $19.01 as ADR Nears Midpoint of Trading Range - Time Weighted Price
- Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 2nd Quarter on October 29
- A Takeda spinout builds case for its Parkinson’s drug
- Ghana’s Prof. Priscilla Kolibea Mante Leads KNUST Team to Secure $5.1 Million Takeda Global CSR Award
- List of 20 Acquisitions by Takeda (Oct 2026)
Headlines from the last 30 days, linking to the original publishers. See all market news →